Spinelli Matthew A, Scott Hyman M, Vittinghoff Eric, Liu Albert Y, Gonzalez Rafael, Morehead-Gee Alicia, Gandhi Monica, Buchbinder Susan P
Division of HIV, ID, and Global Medicine, University of California, San Francisco.
Bridge HIV, San Francisco Department of Public Health, University of California, Los Angeles.
Open Forum Infect Dis. 2019 Feb 26;6(4):ofz101. doi: 10.1093/ofid/ofz101. eCollection 2019 Apr.
Maintaining retention in preexposure prophylaxis (PrEP) care among diverse patient populations will be needed to support PrEP's efficacy. We characterized patterns of PrEP care retention in a US municipal primary care health network and examined whether missed visits, a metric of care retention that is easy to evaluate in clinic, are associated with subsequent discontinuation.
We included individuals on PrEP from July 2012 until August 2017 in the San Francisco Primary Care Clinics, a 15-clinic municipal health network. We categorized PrEP usage patterns as follows: early discontinuation (<90 days), later discontinuation (after ≥90 days), and continuing use at the end of follow-up. We first examined early discontinuation using adjusted Poisson regression. In patients who continued PrEP for ≥90 days, we examined factors associated with late discontinuation.
Of the 364 individuals who started PrEP, 16% discontinued PrEP before 90 days, 46% discontinued later, and 38% were retained in care over a median 12 months of observation. Transgender women were more likely to discontinue PrEP early (adjusted risk ratio; 2.16; 95% confidence interval, 1.36-3.49), and younger users were more likely to discontinue late (0.82 per 10-year increase in age; .70-.96), as were persons who use illicit drugs (1.59; 1.02-2.47). Missed visits during use of PrEP were associated with future discontinuation (adjusted risk ratio, 1.52; 95% confidence interval, 1.14-2.03). Later year of current PrEP use was associated with both early and late discontinuation.
Diverse populations may require differentiated care to continue PrEP. Missed visits should trigger tailored interventions to maximize the impact of PrEP.
为支持暴露前预防(PrEP)的疗效,需要在不同患者群体中维持PrEP治疗的持续性。我们对美国一个城市初级保健健康网络中PrEP治疗的持续性模式进行了特征描述,并研究了漏诊就诊(这是一种在诊所中易于评估的治疗持续性指标)是否与后续停药有关。
我们纳入了2012年7月至2017年8月期间在旧金山初级保健诊所(一个由15家诊所组成的城市健康网络)接受PrEP治疗的个体。我们将PrEP使用模式分类如下:早期停药(<90天)、后期停药(≥90天后)以及随访结束时仍在持续使用。我们首先使用校正后的泊松回归分析早期停药情况。在持续PrEP治疗≥90天的患者中,我们研究了与后期停药相关的因素。
在开始PrEP治疗的364名个体中,16%在90天前停药,46%在后期停药,38%在中位12个月的观察期内持续接受治疗。跨性别女性更有可能早期停用PrEP(校正风险比;2.16;95%置信区间,1.36 - 3.49),年轻使用者更有可能后期停药(年龄每增加10岁,风险比为0.82;0.70 - 0.96),使用非法药物者也是如此(1.59;1.02 - 2.47)。PrEP治疗期间的漏诊就诊与未来停药有关(校正风险比,1.52;95%置信区间,1.14 - 2.03)。当前PrEP使用的较晚年份与早期和后期停药均有关。
不同人群可能需要差异化的护理以继续接受PrEP治疗。漏诊就诊应引发针对性的干预措施,以最大化PrEP的影响。